Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT8MG4S)

DTT Name Transferrin receptor protein 1 (TFRC)
Synonyms Trfr; TfR1; TfR; TR protein; T9; P90; CD71 antigen; CD71
Gene Name TFRC
DTT Type
Clinical trial target
 [1]
BioChemical Class
Peptidase
UniProt ID
TFR1_HUMAN
TTD ID
T33976
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPK
RCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPAAR
RLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREFKLSK
VWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTK
KDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGH
AHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTD
STCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAWGPGAAKSG
VGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLSSLHLKAFT
YINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNA
AFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIK
LTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDFFRATSRLTTDF
GNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRK
QNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
Function
Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system. A second ligand, the heditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site. Positively regulates T and B cell proliferation through iron uptake. Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes.
KEGG Pathway
HIF-1 signaling pathway (hsa04066 )
Endocytosis (hsa04144 )
Phagosome (hsa04145 )
Ferroptosis (hsa04216 )
Hematopoietic cell lineage (hsa04640 )
Reactome Pathway
Cargo recognition for clathrin-mediated endocytosis (R-HSA-8856825 )
Clathrin-mediated endocytosis (R-HSA-8856828 )
RHOA GTPase cycle (R-HSA-8980692 )
RHOB GTPase cycle (R-HSA-9013026 )
RHOC GTPase cycle (R-HSA-9013106 )
CDC42 GTPase cycle (R-HSA-9013148 )
RAC1 GTPase cycle (R-HSA-9013149 )
RAC2 GTPase cycle (R-HSA-9013404 )
RHOQ GTPase cycle (R-HSA-9013406 )
RHOH GTPase cycle (R-HSA-9013407 )
RHOG GTPase cycle (R-HSA-9013408 )
RHOJ GTPase cycle (R-HSA-9013409 )
RAC3 GTPase cycle (R-HSA-9013423 )
Transferrin endocytosis and recycling (R-HSA-917977 )
RND2 GTPase cycle (R-HSA-9696270 )
RND1 GTPase cycle (R-HSA-9696273 )
Golgi Associated Vesicle Biogenesis (R-HSA-432722 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CX2029 DMYTTBK Aggressive cancer 2A00-2F9Z Phase 1/2 [2]
ABBV-CX-2029 DMUSOM9 Hematologic tumour 2B33.Y Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Biomarkers for the differentiation of anemia and their clinical usefulness. J Blood Med. 2013 Mar 20;4:11-22.
2 Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336.
3 Clinical pipeline report, company report or official report of AbbVie.